Suppressors and activators of JAK-STAT signaling at diagnosis and relapse of acute lymphoblastic leukemia in Down syndrome.

doi:10.1073/pnas.1702489114

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Suppressors and activators of JAK-STAT signaling at diagnosis and relapse of acute lymphoblastic leukemia in Down syndrome.

Proceedings of the National Academy of Sciences of the United States of America - 16 May 2017

Schwartzman Omer, Savino Angela Maria, Gombert Michael, Palmi Chiara, Cario Gunnar, Schrappe Martin, Eckert Cornelia, von Stackelberg Arend, Huang Jin-Yan, Hameiri-Grossman Michal, Avigad Smadar, Te Kronnie Geertruy, Geron Ifat, Birger Yehudit, Rein Avigail, Zarfati Giulia, Fischer Ute, Mukamel Zohar, Stanulla Martin, Biondi Andrea, Cazzaniga Giovanni, Vetere Amedeo, Wagner Bridget K, Chen Zhu, Chen Sai-Juan, Tanay Amos, Borkhardt Arndt, Izraeli Shai

Abstract excerpt

Children with Down syndrome (DS) are prone to development of high-risk B-cell precursor ALL (DS-ALL), which differs genetically from most sporadic pediatric ALLs. Increased expression of cytokine receptor-like factor 2 (CRLF2), the receptor to thymic stromal lymphopoietin (TSLP), characterizes about half of DS-ALLs and also a subgroup of sporadic "Philadelphia-like" ALLs. To understand the pathogenesis of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cell Line, Tumor

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Down Syndrome

Share to Janus Kinases

Share to Precursor Cell Lymphoblastic Leukemia-Lymphoma

Share to Receptors, Cytokine

Share to Recurrence

Share to STAT Transcription Factors

Share to Ubiquitin Thiolesterase

Source

Open in PubMed Open full text

Identifiers

PMID: 28461505
DOI: 10.1073/pnas.1702489114
PMCID: PMC5441776

Genes

JAK2
CRLF2
TSLP

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Suppressors and activators of JAK-STAT signaling at diagnosis and relapse of acute lymphoblastic leukemia in Down syndrome.PMID 28461505Read ↗

Frequent cases of RAS-mutated Down syndrome acute lymphoblastic leukaemia lack JAK2 mutations.Semantic proximity Read ↗

Genomic landscape of Down syndrome-associated acute lymphoblastic leukemia.Semantic proximity Read ↗

The acute lymphoblastic leukemia of Down Syndrome - Genetics and pathogenesis.Semantic proximity Read ↗

Hematologic Neoplasms Associated with Down Syndrome: Cellular and Molecular Heterogeneity of the Diseases.Semantic proximity Read ↗

RAS activation via CRLF2 signaling is a widespread mechanism in Down syndrome acute lymphoblastic leukemia regardless of RAS mutationsSemantic proximity Read ↗

Down syndrome and leukemia: insights into leukemogenesis and translational targets.Semantic proximity Read ↗

Constitutive Activation of RAS/MAPK Pathway Cooperates with Trisomy 21 and Is Therapeutically Exploitable in Down Syndrome B-cell LeukemiaSemantic proximity Read ↗

Specific JAK2 mutation (JAK2R683) and multiple gene deletions in Down syndrome acute lymphoblastic leukemia.Semantic proximity Read ↗

Down syndrome acute lymphoblastic leukemia, a highly heterogeneous disease in which aberrant expression of CRLF2 is associated with mutated JAK2: a report from the International BFM Study Group.Semantic proximity Read ↗

Landscape of driver mutations and their clinical effects on Down syndrome-related myeloid neoplasms.Semantic proximity Read ↗

Down syndrome and leukemia: An insight into the disease biology and current treatment options.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.